Inactive Instrument

Analyst Reco. TURG POIN

Equities

TPTX

US90041T1088

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72	13/06/22	MT
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101	13/06/22	MT
Oppenheimer Downgrades Turning Point Therapeutics to Market Perform From Outperform	06/06/22	MT
Cowen Downgrades Turning Point Therapeutics to Market Perform from Outperform	06/06/22	MT
HC Wainwright Cuts Turning Point Therapeutics to Neutral From Buy, Price Target to $76 From $161	06/06/22	MT
Wells Fargo Downgrades Turning Point Therapeutics to Equalweight From Overweight, Adjusts Price Target to $76 From $85	06/06/22	MT
US Stocks Finish Holiday-Shortened Week Lower as May Unemployment Rate Holds Steady	03/06/22	MT
Equities Fall Midday After May Unemployment Rate Remains Unchanged	03/06/22	MT
Midday Report: US Equity Indices Fall After May Unemployment Rate Remains Unchanged	03/06/22	MT
Wedbush Downgrades Turning Point Therapeutics to Neutral From Outperform, Adjusts Price Target to $76 From $61 on Bristol-Myers Squibb Offer	03/06/22	MT
Goldman Sachs Adjusts Price Target for Turning Point Therapeutics to $116 From $143, Keeps Buy Rating	24/05/22	MT
BofA Securities Starts Turning Point Therapeutics at Buy With $58 Price Target	20/05/22	MT
SVB Securities Adjusts Turning Point Therapeutics' Price Target to $101 from $107, Keeps Outperform Rating	11/05/22	MT
Wedbush Lowers Turning Point Therapeutics' Price Target to $61 from $93, Keeps Outperform Rating	11/05/22	MT
Wedbush Adjusts Price Target on Turning Point Therapeutics to $93 From $101, Keeps Outperform Rating	13/04/22	MT
Guggenheim Adjusts Price Target on Turning Point Therapeutics to $72 From $82, Reiterates Buy Rating	25/03/22	MT
HC Wainwright Adjusts Turning Point Therapeutics' Price Target to $161 From $162, Keeps Buy Rating	22/03/22	MT
Wedbush Adjusts Price Target on Turning Point Therapeutics to $101 From $125, Citing Cost of Capital, Product Launch Adjustments; Outperform Rating Kept	01/03/22	MT
Wells Fargo Adjusts Turning Point Therapeutics' Price Target to $85 from $120, Maintains Overweight Rating	10/02/22	MT
Oppenheimer Adjusts Turning Point Therapeutics' Price Target to $105 From $115, Maintains Outperform Rating	21/01/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TURG POIN

Equities

TPTX

US90041T1088

Analyst Reco.

Filters